How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

507 results for

Unintentional Weight Loss Causes


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

481. Management of dyspepsia in adults in primary care

use. - Urgent specialist referral for endoscopic investigation. is indicated for patients of any age with dyspepsia when presenting with any of the following: chronic gastrointestinal bleeding, progressive unintentional weight loss, progressive difficulty swallowing, persistent vomiting, iron deficiency anaemia, epigastric mass or suspicious barium meal. - Routine endoscopic investigation of patients of any age, presenting with dyspepsia and without alarm signs, is not necessary. However (...) for Clinical Excellence (NICE) 2004: 45 Authors' objectives This report provides guidelines on the management of dyspepsia in adults in primary care. Authors' conclusions The following have been identified as priorities for implementation. Referral for endoscopy - Review medications for possible causes of dyspepsia (for example, calcium antagonists, nitrates, theophyllines, bisphosphonates, corticosteroids and non-steroidal anti-inflammatory drugs [NSAIDs]). In patients requiring referral, suspend NSAID

2004 Health Technology Assessment (HTA) Database.

482. Natural Orifice Translumenal Endoscopic Surgery for intra-abdominal surgery: a systematic review

Table 3: Sites chosen for NOTES viscerotomy 21 Table 4: NOTES gastrotomy closure 24 Table 5: Success of visualisation using NOTES 27 Table 6: Success of NOTES anastomosis creation 32 Table 7: Success of NOTES cholecystectomy 33 Table 8: Success of NOTES biopsy 34 Table 9: Duration of Surgery 38 Table 10: Post-operative mortality 39 Table 11: Post-operative feeding and weight gain 40 Table 12: Infection-related complications 41 SAGES 2006 Abstracts 69 Excluded Studies 75 - ASERNIP-S REVIEW OF NATURAL (...) randomised trials or from at least one high quality randomised controlled trial of sufficient power. The component studies should show consistent results, the differences between the interventions being compared should be large enough to be important, and the results should be precise with minimal uncertainty. Average Most of the evidence is from high quality quasi-randomised controlled trials, or from non-randomised comparative studies without significant flaws, such as large losses to follow-up


483. Nursing Management of Hypertension

give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. The views expressed in this guideline do not necessarily reflect those of the Ministry of Health and Long-Term Care. Any reference throughout the document to specific pharmaceutical products as examples does not imply endorsement of any of these products. Copyright (...) ) Diet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .108 Appendix I – Reducing Sodium the DASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 Appendix J – Recording Food Habits and DASH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .115 Appendix K – Canadian Body Weight Classification System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .116

2005 Registered Nurses' Association of Ontario

484. Effectiveness reviews in health promotion

of effort and to ensure that new reviews build on previous reviews. ? Clear reporting of review methods should be encouraged. For example, a checklist could be provided to authors and journal editors covering the key stages in conducting a systematic review (methods for searching, inclusion criteria, validity criteria). ? Those commissioning and conducting effectiveness reviews should agree a common framework for how reviews in health promotion should be carried out, including the weighting of primary (...) for implementing search strategies and sorting the search results can be reduced by using search strategies with higher specificity. Consequent loss of sensitivity can be minimised by combining a comprehensive search based on subject- and prevention- related terminology with specific study design. This was found to be an acceptable strategy on Medline, but loss of sensitivity may be more severe on other databases especially those with a less comprehensive or no indexing system for study design. The use

1999 EPPI Centre

485. Risk Assessment and Prevention of Pressure Ulcers

liability , with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceutical products as examples does not imply endorsement of any of these products. Copyright First published in 2002 by the Registered Nurses’ Association of Ontario. This document was revised in March 2005. With the exception of those portions of this document for which a specific prohibition or limitation against (...) , therapeutic positioning, support surfaces, and other non-pharmacological interventions. Monitor level of pain on an on-going basis, using a valid pain assessment tool. 3.3b Consider the client’s risk for skin breakdown related to the loss of protective IV sensation or the ability to perceive pain and to respond in an effective manner (e.g., impact of analgesics, sedatives, neuropathy, etc.). 3.3c Consider the impact of pain on local tissue perfusion. IV *See page 14 for an Interpretation of Evidence.3.4

2002 Registered Nurses' Association of Ontario

486. Prevention of Falls and Fall Injuries in the Older Adult

constitute a liability nor discharge from liability. While every effort has been made to ensure the accuracy of the contents at the time of publication, neither the authors nor RNAO give any guarantee as to the accuracy of the information contained in them nor accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceutical products as examples does not imply (...) . The use of explicit, systematic methods in reviews limits bias (systematic errors) and reduces chance effects, thus providing more reliable results upon which to draw conclusions and make decisions (Alderson, Green, & Higgins, 2004). Background Context Falls Statistics in Canada According to the Canadian Institute for Health Information (CIHI, 2000), falls are the primary cause of injury admissions to Canada’s acute care hospitals, accounting for 54.4% of all injury hospitalizations and 75.7% of all

2002 Registered Nurses' Association of Ontario

487. Abnormal Weight Loss

and European Guidelines. You may find the article more useful, or one of our other . In this article In This Article Abnormal Weight Loss In this article Unintentional weight loss is a decrease in body weight that is not voluntary. Weight loss is a very nonspecific symptom but may be indicative of a serious underlying pathology. Weight loss will occur with inadequate food intake, malabsorption, increased metabolism, or a combination of factors. Aetiology There are many causes of abnormal weight loss (...) as the underlying cause should prompt urgent referral for further assessment in secondary care. [ ] Management is otherwise directed at the cause of weight loss and may include physical, psychological and social (eg, 'meals at home scheme', respite care) interventions. The elderly are particularly at risk and nutritional evaluation should be part of any routine geriatric assessment. [ ] Complications [ ] Elderly patients with unintentional weight loss are at higher risk of infection and depression. Abnormally

2008 Mentor

488. Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

progression with either of the following manifestations: Moderate-severe right upper quadrant pain and unintentional weight loss > 10% Decline in Karnofsky performance status > 10 points At least a 20% increase in the sum of the longest diameters of target lesions in the liver within the past 12 months No more than 75% replacement of normal liver by neuroendocrine tumor No more than 20% arteriovenous lung shunting on a technetium Tc 99m macro-aggregated albumin nuclear scan No equivocal, nonmeasurable (...) , 2012 Sponsor: Vanderbilt-Ingram Cancer Center Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Steven Meranze, MD, Vanderbilt-Ingram Cancer Center Study Details Study Description Go to Brief Summary: RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works

2007 Clinical Trials

489. Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: histologic or cytologic proof of single primary non-small cell lung cancer No prior chemotherapy or radiation therapy no prior malignancy Exclusion Criteria: pregnancy or breastfeeding serious concomitant systemic disorder unintentional weight loss greater than 10% Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) Survival [ Time Frame: 2 years ] Secondary Outcome Measures : Number of Patients With Overall Tumor Response [ Time Frame: randomization and every 3 months up to 2 years of post-study followup ] Progression-Free Survival [ Time Frame: baseline to measured progressive disease up to 2057 days ] Overall Survival [ Time Frame: baseline to date of death from any cause up to 2057 days ] Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization [ Time Frame: baseline to 3 months after last dose of study

2005 Clinical Trials

490. S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

OR Zubrod performance status 2 with no co-morbidities or meeting 1 of the following criteria: No co-morbidities FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L DLCO > 10 mL/mm Hg/min Albumin < 0.85 times lower limit of normal Unintentional weight loss > 10% within the past 6 months Controlled congestive heart failure which, in the opinion of the investigator, may become decompensated due to radiotherapy FEV_1 < 2 L OR < 1 L with estimated contralateral FEV_1 ≥ 0.6 L Absolute neutrophil (...) form the date of enrollment until the date of death due to any cause. Patients last known to be alive are censored at the date of last contact. Progression-free Survival. [ Time Frame: At week 10, week 22, and then every 3 months until progression for up to 3 years after enrollment. ] Duration from the date of enrollment until the date of progression (as defined by RECIST: >= 20% increase over baseline in the sum of longest diameters, or appearance of new lesions, or non-measurable disease

2006 Clinical Trials

491. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. (PubMed)

)) relationship. We investigated the impact of recombinant human GH (rhGH) treatment on a-vO(2) difference and the Q-VO(2) relationship during submaximal exercise by randomizing 12 HIV-infected patients (mean +/- sem: age, 43.3 +/- 1.5 yr; body mass, 69.5 +/- 2.9 kg; body mass index, 22.4 +/- 0.9 kg/m(2); maximum oxygen consumption, 33.6 +/- 1.5 ml/kg x min), with documented unintentional weight loss (>or=10% within the preceding 12 months) despite antiretroviral therapy, to receive 3 months of rhGH (6 mg/d (...) Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial. The arteriovenous oxygen difference (a-vO(2) difference), a measure of peripheral muscle oxygen extraction-utilization during exercise, is reduced in antiretroviral-treated patients with human immunodeficiency virus (HIV), thus causing a shift in the cardiac output-oxygen consumption (Q-VO(2

Full Text available with Trip Pro

2004 The Journal of clinical endocrinology and metabolism

492. Bedside Assessment of Fall Risk in Emergency Department Elders

in order to find out how predictive the balance tests are in determining the risk of future falls. Condition or disease Accidental Falls Detailed Description: Falls are one of the most significant health risks to older Americans. In the U.S., 30-60% of community dwelling elders will fall each year.Studies have found rates of serious injury among elders who fall to range from 5-24%. Five percent of those who fall are hospitalized. Among elders, falls cause 2/3 of the deaths due to unintentional injury (...) , the 6th leading cause of death in this age group. Additional major morbidity due to falls includes loss of independence as well as anxiety due to fear of falling. This results in limitation of function and often in a requirement for long-term care. Up to 40% of nursing home admissions are due to falls or fear of falling. Expenditures for fall-related injuries account for 6% of all medical expenditures in geriatric patients. Several interventions have been proven effective to reduce rates of fall

2007 Clinical Trials

493. Ghrelin in Older Women

" will increase levels of growth hormone in the blood and increase appetite. Ghrelin is a naturally occurring hormone that is produced mostly by the stomach and causes secretion of another hormone called growth hormone. It also increases short-term appetite and may lower the amount of inflammation in the body. Some people lose their appetite as they age and have unintentional weight loss. This may be caused by a break in the communication between the stomach and the brain. We are particularly interested (...) Ages Eligible for Study: 70 Years and older (Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Frail group: Women aged 70 or greater Able to give informed consent Undiagnosed weight loss (>5% over the previous year) Two of the following four criteria (from Fried L et al, 2001): low grip strength, slow walking speed, subjective exhaustion, low levels of physical activity Healthy group: Women aged 70 or greater Able to give informed consent

2007 Clinical Trials

494. Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.) Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss Contacts and Locations Go (...) to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body

2007 Clinical Trials

495. Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

lymph nodes, nodal clusters, or progressive lymphadenopathy; Grade 2 or 3 fatigue, fever >/= 100.5 degrees F, night sweats for > 2 weeks w/o documented infection, presence of weight loss >/= 10% over the preceding 6 months; Progressive lymphocytosis with increase in lymphocyte count of >/= 50% over a 2-month period or an anticipated doubling time of < 6 months. Serum bilirubin less than 2mg/dL, serum creatinine less than 2mg/dL unless abnormality is considered due to CLL by investigator. The Eastern (...) Cooperative Oncology Group (ECOG) Performance Status < 3. Patients must sign an informed consent indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital. Sexually active women of childbearing potential must use birth control during study in manner that risk of failure is minimized. Prior to study enrollment women of childbearing potential must be advised of importance of avoiding pregnancy during trial and potential risk factors for unintentional

2006 Clinical Trials

496. Gastric outlet obstruction secondary to acid ingestion in children. (PubMed)

between ingestion and the first signs of GOO, weight loss, treatment, complications, duration of hospital stay, and long-term follow-up were reviewed.GOO was not observed in any of the children admitted for alkaline ingestion, whereas GOO developed in 8 of 98 children (8.2%) in a mean period of 26.7 +/- 10 days after the ingestion of acid substances. Presenting symptoms were frequent nonbilious vomiting and marked weight loss. All had pyloric obstructions in the upper gastrointestinal series (...) Gastric outlet obstruction secondary to acid ingestion in children. Gastric outlet obstruction (GOO) is a well-known complication of acid ingestion. However, most reports deal with adults. In this report, the authors present their experience with the treatment of acid-induced GOO in children.The records of patients admitted for unintentional ingestion of corrosive agents between 1980 and 2002 were reviewed retrospectively. Data concerning age at ingestion, type of ingested substance, time

2004 Journal of Pediatric Surgery

497. Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3

sample. Have at least one of the following: Oral candidiasis. Herpes zoster during the last 3 years. Oral hairy leukoplakia during the past three years. Chronic ( > 30 day period), recurrent seborrheic dermatitis, or topical, pruritic folliculitis (itchy bumps). Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight. Chronic fatigue present for the past 6 months, which has interfered with normal activity at least 1 to 2 times per week. HIV antibody positive as determined (...) with the exception of Zidovudine. Cancer chemotherapeutic agents. Anti-metabolites and alkylating agents. All investigational non-FDA approved drugs. Patients with the following are excluded: Clinically significant diarrhea (> 3 liquid stools per day for > 7 days) without definable cause, within 6 months prior to enrollment). Diarrhea, as above, with known, non-HIV related cause occurring within one month prior to enrollment. Meets CDC criteria for AIDS classification. Chronic fever (> 38.5 C persisting for more

1999 Clinical Trials

498. A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

to entry. Unexplained diarrhea defined as three or more liquid stools per day, persisting more than 7 days within 2 years prior to entry. Unintentional weight loss of greater than 10 lbs. or more than 10 percent of usual body weight within 2 years prior to study entry. Oral hairy leukoplakia at any time prior to entry. Oral candidiasis unrelated to the use of antibiotic therapy for more than 2 weeks within 2 years prior to entry or within the past 3 months. Herpes zoster within 2 years prior to entry (...) candidiasis, and localized cutaneous herpes simplex or zoster infections. Probenecid. Aspirin on a regular basis, or for more than 72 hours without contacting the investigator. Drugs causing neutropenia or significant risk of nephrotoxicity. Patients in Study A with the following prior conditions are excluded: AIDS-defining opportunistic infection or malignancy. Unexplained temperature greater than 38 C for more than 5 consecutive days or more than 10 days in any 30-day period in the 2 years prior

1999 Clinical Trials

499. A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

. Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight). History of sensitivity to the study medication. Malignancies requiring the use of cytotoxic chemotherapy. Coma. Diffuse central white matter lesions. Negative serology for Toxoplasma as performed at the Palo Alto Medical Foundation (unless biopsy is positive). Lymphoma of the central nervous system. Cerebral Kaposi's sarcoma. Hemorrhagic diathesis (...) patients with AIDS. Toxoplasmic encephalitis (encephalitis caused by Toxoplasma gondii) is the most frequent cause of focal central nervous system infection in patients with AIDS. If untreated, the encephalitis is fatal. At present, it is standard practice to give a combination of pyrimethamine and sulfadiazine to treat toxoplasmic encephalitis. The high frequency of sulfonamide-induced toxicity in AIDS patients often makes completion of a full course of therapy difficult. There is some information

1999 Clinical Trials

500. A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients

maintenance. Required: Stable prescribed dose of zidovudine (AZT) of at least 500 mg/day. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Prior history of toxoplasmic encephalitis. Unable to take oral medication reliably or have a malabsorption syndrome (i.e., 3 or more loose stools/day for at least 4 weeks associated with an unintentional weight loss of = or > 10 percent of body weight). History of sensitivity to the study medications. Concurrent (...) the development of toxoplasmosis in AIDS patients or delay the subsequent return of toxoplasmic encephalitis. Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. The best treatment for this disease has not been determined. Presently it is standard practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about the pharmacokinetics of pyrimethamine

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>